Company news

MiMedx Group, Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MIMEDX Addresses Presentation by Prescience Point

June 1, 2022

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

May 30, 2022

MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders

May 30, 2022

Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

May 24, 2022

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

May 19, 2022

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

May 17, 2022

MIMEDX Mails Letter to Shareholders

May 15, 2022

MIMEDX Comments on Prescience Point’s False and Misleading Statements

May 8, 2022

MIMEDX to Participate at Upcoming Investor Conferences

May 4, 2022

MIMEDX Announces First Quarter 2022 Operating and Financial Results

May 2, 2022

MIMEDX Comments on Prescience Point’s Recent Filing

April 28, 2022

MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4

April 19, 2022

MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring

April 4, 2022

MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference

March 14, 2022

MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

February 27, 2022

Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care

February 15, 2022

MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28

February 13, 2022

MIMEDX Outlines Key Strategic Milestones for 2022

January 9, 2022

MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference

December 21, 2021

MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day

December 6, 2021

MIMEDX Announces Speakers for December 7 Investor Day

November 29, 2021

MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference

November 21, 2021

Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM) Outperforms Standard of Care in Select Mohs Defect Reconstructions

November 16, 2021

MIMEDX Announces Third Quarter 2021 Operating and Financial Results

November 1, 2021

Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy

October 31, 2021

MIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3

October 19, 2021

MIMEDX to Host Virtual Investor Day on December 7, 2021

October 13, 2021

MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology

September 12, 2021

MIMEDX Announces Effectiveness of Shelf Registration Statement

September 7, 2021

MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission

August 26, 2021

Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers (LEDUs)

August 16, 2021

MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs

August 11, 2021

MIMEDX Announces Second Quarter 2021 Operating and Financial Results

August 2, 2021

MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4

July 19, 2021

MIMEDX Joins Russell 3000® and 2000® Indexes

June 27, 2021

MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference

June 15, 2021

New Study Demonstrates Potential for MIMEDX Purion® Processed Dehydrated Human Amnion/Chorion Membrane to Modulate Pathological Scar Tissue Formation

June 14, 2021

MIMEDX Receives Regulatory Approval to Commercialize EPIFIX® in Japan

June 7, 2021

MIMEDX to Participate at the Jefferies Virtual Healthcare Conference

May 26, 2021

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders

May 24, 2021

MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting

May 11, 2021

MIMEDX Announces Collaborative Agreement with the Wake Forest Institute for Regenerative Medicine

May 5, 2021

MIMEDX Urges Shareholders to Consider Prescience Point’s Motivations Before Voting Their Shares at the Company’s Annual Meeting

May 3, 2021

MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

May 2, 2021

MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

April 27, 2021

MiMedx Announces First Quarter 2021 Financial and Operating Results

April 27, 2021

MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29

April 21, 2021

MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology

April 18, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 62 decks. Every deck is listed under its year.